$GILD

Mercier Johanna sold $390K of GILD

Mercier Johanna (Chief Comm & Corp Aff Officer) sold 3,000 shares of GILEAD SCIENCES, INC. (GILD) at $129.92 ($0.39M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mercier Johanna
Published Jul 16, 2026, 8:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GILD
Neutral
high confidence
Mentioned
$GILD
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GILDNeutralLow
01

Why it matters

The disclosure provides transparency on an officer’s scheduled open-market sale but does not introduce new company fundamentals.

02

Market read

Traders may treat this as routine insider activity with minimal impact unless paired with other new catalysts.

03

What to watch

The article does not state whether the sale was part of a larger scheduled program, nor does it provide context on total holdings changes beyond the post-transaction share count.

Relevance 3/10Novelty 2/10Timing: Filed after-hours on 2026-07-16, covering a sale dated 2026-07-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Gilead Sciences, Inc.

Company-level read

Ticker impact

$GILDNeutralHigh confidence
Context

SEC Form 4 shows Gilead officer Mercier Johanna sold 3,000 shares on 2026-07-15 for about $389,758 under a 10b5-1 plan.

Expected impact

Likely negligible near-term price impact; any effect would be sentiment-only and small.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operational, financial, or regulatory information.

Market effects

No sector read-through; this is company-specific insider transaction data without new guidance or events.

None.

None.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so traders may watch for follow-on filings or changes in selling pace.

Key entities

  • Gilead Sciences, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Mercier Johanna

    Chief Comm & Corp Aff Officer who sold shares.

  • 10b5-1 plan

    Pre-arranged plan cited as Yes, indicating the sale was scheduled.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GILDHighAI 8/10

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?

Gilead Sciences (GILD) received three FDA approvals in four months, boosting its stock 21% YTD. Recent approvals include Bixlenvo for HIV and Trodelvy for breast cancer. The company expects more approvals, including anito-cel for multiple myeloma by year-end. Gilead's Q2 revenue was $7.6B, up 8% YoY, with strong HIV drug sales. The company raised its dividend to $0.82, yielding 2.15%.

$GILDHighAI 9/10

Tablet Regimen for Virologically Suppressed Adults Living with HIV

The FDA approved Gilead Sciences' Bixlenvo, a once-daily single-tablet HIV treatment for virologically suppressed adults. The drug combines bictegravir and lenacapavir, simplifying therapy and reducing pill burden. Clinical trials showed non-inferior viral suppression rates and improved health metrics. Bixlenvo is designed for patients with complex treatment histories or resistance challenges.

$GILDHighAI 9/10

A new once-daily pill to treat HIV just got the FDA’s green light

The FDA approved Gilead Sciences' once-daily HIV pill, Bixlenvo, for adults with suppressed HIV who cannot use current single-pill treatments. It combines bictegravir and lenacapavir, with a list price of $4,595 per month. Gilead aims to provide more treatment options, especially for older patients with complex regimens. According to the company, this group represents about 5% of HIV patients in the U.S.

$AMGNMed

Trump Announces New Drug Pricing Deals With Nine Manufacturers

President Trump announced new voluntary drug pricing agreements with nine pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Merck, to lower U.S. prescription drug prices. The deals, part of the TrumpRx platform, aim to align prices with those in other wealthy nations. Companies receive tariff relief in exchange for participation. Critics note limited impact on patient costs and lack of public contract details.